Gastrointestinal stromal tumors: Report of an audit and review of the literature

European Journal of Cancer Prevention

Volumn 18, Issue 2, 2009, Pages 106-116

  Biasco, Guido ^a   Velo, Daniela ^b   Angriman, Imerio ^c   Astorino, Maria ^a   Baldan, Anna ^b   Baseggio, Matteo ^d   Basso, Umberto ⁱ   Battaglia, Giorgio ^e   Bertin, Matteo ^c   Bertorelle, Roberta ⁱ   Bocus, Paolo ^e   Brosolo, Piero ^j   Bulzacchi, Andrea ⁱ   Cannizzaro, Renato ^k   Da Dalt, Gian Franco ^f   Di Battista, Monica ^a   Errante, Domenico ^l   Fedrigo, Marny ^g   Frustaci, Sergio ^k   Lionetti, Ivana ⁱ   Massani, Marco ^m   Mencarelli, Roberto ^g   Montesco, Maria Cristina ^g   Norberto, Lorenzo ^c   Pantaleo, Maria Abbondanza ^a   Pasquali, Claudio ^h   Pastorelli, Davide ⁱ   Rossi, Carlo Remigio ^d   Ruffolo, Cesare ^c   Salvagno, Luigi ^l   Saponara, Maria Stella ^a   Vittadello, Fabrizio ^f   Zaccaria, Francesco ^f   Zovato, Stefania ⁱ   Farinati, Fabio ^b,n   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Gastroenterology   (Italy)

^c Clinica Chirurgica 2a   (Italy)

^d Clinica Chirurgica II   (Italy)

^e Clinica Chirurgica III   (Italy)

^f General Surgery

^g Pathology Section

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j Tolmezzo General Hospital   (Italy)

^k Aviano National Cancer Institute   (Italy)

^l OSPEDALE CA FONCELLO   (Italy)

^m Regional Hospital C Foncello   (Italy)

ⁿ UNIVERSITY HOSPITAL OF PADOVA   (Italy)

more..

Author keywords

Audit gastrointestinal stromal tumors; Oncology

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; SUNITINIB;

AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FAMILIAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; HUMAN; LAPAROSCOPIC SURGERY; MEDICAL AUDIT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

CLINICAL AUDIT; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MULTICENTER STUDIES AS TOPIC; MUTATION; PHOSPHOTRANSFERASES; PROGNOSIS;

EID: 61449255585     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32830c8da8     Document Type: Article

References (67)

1. Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A, et al. (2007). Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31:113-120.
2. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. (2004). Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumours. J Clin Med 45:357-365.
3. Antonescu CR (2006). GIST pathogenesis, familial GIST and animals models. Semin Diagn Pathol 23:63-69.
4. Antonescu CR, Besmer P, Guo T, Arkun K, Horn G, Koryotowski B, et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-4190.
5. Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C, Larizza L (2001). Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92:657-662.
6. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B (2006). Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist 11:9-20.
7. Bergmann F, Gunawan B, Hermanns B, Hoer J, Schumpelick V, Fuzesi L (1998). Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies. Verh Dtsch Ges Pathol 82: 275-278.
8. Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, et al. (2006). Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 20:157-163.
9. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. (2005). Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16:566-578.
10. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH (1991). Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. Embo J 10:4121-4128.
11. Bussolati G (2005). Of GISTs and eGISTs, ICCs and ICs. Virchows Arch 447:907-908.
12. Carney JA (1999). Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74:543-552.
13. Carney JA, Stratakis CA (2002). Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney1s triad. Am J Med Genet 108:132-139.
14. Chetty R (2008). Small and microscopically detected gastrointestinal stromal tumors: an overview. Pathology 40:9-12.
15. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. (2007). Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759.
16. Corless CL, Reicher JA, Heinrich MC (2004). Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825.
17. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. (2005). PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364. This study is the most definitive analysis of PDGFRA mutations.
18. Daum O, Vanecek T, Sima R, Michal M (2006). Gastrointestinal stromal tumor: update. Klinicka Onkologie 19:203-211.
19. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58.
20. De Matteo RP, Heinrich MC, EI-Rifai WM, Demetri Q (2002). Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466-477.
21. Debiec-Rychter M, Lasota J, Sariomo-Rikala M, Kordek R, Miettinen M (2001). Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 128: 24-30.
22. Debiec-Rychter M, Sciot R, Le Cesne A, Shlemmer M, Hohenberger P, van Oosterom AT, et al., on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastrointestinal Trials Group (2006). KIT mutations and dose selection for imatinib in patients with advanced GIST. Eur J Cancer 42:1093-1103.
23. Demetri GD, Morgan JA. Gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract. UpToDate; 2005. http://www.utdol.com/utd/content. [Accessed 17 July 2006] This succinct update summarizes some of the latest therapies in GIST and other mesenchymal gastrointestinal tumors.
24. Desai J, Maki R, Heinrich MC, Fletcher JA, Ryan D, Morgan JA, et al. Activity and tolerability of the multitargeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. In: Program and Abstracts of the American Society of Clinical Oncology 2004 Gastrointestinal Cancer Symposium: Current Status and Future Directions for Prevention and Management; 22-24 January 2004; San Francisco, California; 2004. Abstract 7.
25. Diment J, Tamborini E, Casali P, Gronchi A, Carney JA, Colecchia M (2005). Carney triad: case report and molecular analysis of gastric tumor. Hum Pathol 36:112-116.
26. Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette MT, et al. (2004). Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2:597-605.
27. Reicher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465.
28. Fletcher JA, Corless C, Dimitrijevic S, Von Mehren M, Eisenberg B, Joensuu H, et al. (2003). for the GIST Working Group Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:815.
29. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002). Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484-495.
30. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
31. Heinrich MC, Shoemaker JS, Corless CL, Hollis D, Demetri GD, Bertagnolli MM, Fletcher JA (2005). Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KITb) [abstract]. Proc Am Soc Clin Oncol 23:3s.
32. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774.
33. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580.
34. Huang HY, Li CF, Huang WW, Hu TH, Lin CN, Uen YH, et al. (2007). A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 141:748-756.
35. Imamura M, Yamamoto H, Nakamura N, Oda Y, Yao T, Kakeji Y, et al. (2007). Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 20:529-537.
36. Isozaki K, Terris B, Belghiti J, Isozaki K Schiffmann S, Hirota S, Vanderwinden JM (2000). Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157:1581-1585.
37. Iwahashi M, Takifuji K, Ojima T, Nakamura M, Nakamori M, Nakatani Y, et al. (2006). Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg 30:28-35.
38. Lasota J, Stachura J, Miettinen M (2006). GISTs with PDGFRA exon 14 mutations represent subset of clinically favourable gastric tumors with epithelioid morphology. Lab Invest 86:94-100.
39. Le Cesne A, Perol D, Ray-Coquard I, Bui B, Duffaud F, Rios M, et al. (2005). Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. J Clin Oncol 23:823s. The consequences of imatinib interruption in the treatment of patients with advanced GIST are presented.
40. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, et al. (2005). Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23:2735-2743.
41. Loughrey MB, Beshay V, Dobrovic A, Zalcberg J, Waring PM (2006). Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones. Histopathology 49:99-100.
42. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, et al. (2001). Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120:210-215.
43. Maki R, Fletcher JA, Heinrich M, Morgan JA, George S, Desai J, et al. (2005). Results from a continuation trial of SU11248 in patient (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 24:(Abst9011).
44. Mazur MT, Clark HB (1983). Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 7:507-519.
45. Miettinen M, Lasota J (2006). Gastrointestinal Stromal tumors. Review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med 130:1466-1478.
46. Miettinen M, Lasota J (2006). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83.
47. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J (2001). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 25:1121-1133.
48. Miettinen M, Majidi M, Lasota J (2002). Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38 (Suppl 5): S39-S51.
49. Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006). Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477-489.
50. Min KW, Leabu M (2006). Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med 10:995-101.
51. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. (2005). Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 103:821-829.
52. Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. (2006). Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 139:484-492. Favorable outcomes after laparoscopic resection of gastric GISTs are presented in this Japanese study.
53. Patela S, Zalcberg JR (2008). Optimizing the dose of Imatinib for treatment of gastrointestinal stromal tumors: lesson from the phase III trials. Eur J Cane 44:501-509.
54. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. (2006). Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325-2331. This is the first study describing the rationale for and outcomes of surgery in advanced GIST after treatment with imatinib or sunitinib.
55. Raut CP, Morgan JA, Ashley SW (2007). Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol 23:149-158.
56. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121.
57. Rubin BP, Heinrich MC, Corless CL (2007). Gastrointestinal stromal tumour, tancef 369:1731-1741.
58. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998). CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734.
59. Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M, et al. (2003). High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21:1688-1697.
60. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA (2002). Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898-3905.
61. 18FDG- positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020.
62. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, et al. (2005). Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 29:755-763.
63. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. (2004). A new mutation in the KITATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294-299.
64. Trent JC, Benjamin RS (2006). New developments in gastrointestinal stromal tumor. Curr Opin Oncol 18:386-395.
65. Yalcinkaya U, Yerci O, Koc EU (2007). Significance of p53 expression in gastrointestinal stromal tumors. Hepatogastroenterology 54:140-143.
66. Van H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH, et al. (2003). Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26:221-228.
67. Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR (2005). Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 18:475-484.